Compare MLCI & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLCI | NTRB |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | 21 | 3 |
| Industry | Investment Managers | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.4M | 36.0M |
| IPO Year | N/A | N/A |
| Metric | MLCI | NTRB |
|---|---|---|
| Price | $3.07 | $2.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 12.6K | 9.0K |
| Earning Date | 05-08-2026 | 05-29-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.68 | $2.81 |
| 52 Week High | $8.68 | $8.63 |
| Indicator | MLCI | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 40.49 | 35.39 |
| Support Level | $2.70 | N/A |
| Resistance Level | $3.13 | $3.16 |
| Average True Range (ATR) | 0.13 | 0.12 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 6.56 | 5.72 |
Mount Logan Capital Inc operates as emerging asset management and investment firm focused on investing in public and private debt securities in the North American market. The company's reporting segments include asset management and insurance. The company through its subsidiaries, earns management and incentive fees and servicing fees for providing investment management, monitoring and other services to investment vehicles and advisers. The Asset Management segment comprises all fee generating activities. The Insurance Solutions segment, which derives maximum revenue, consists of two product lines within the insurance business, LTC and MYGA.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.